Research programme: proteolysis targeting chimeric molecules - Boehringer Ingelheim/University of Dundee

Drug Profile

Research programme: proteolysis targeting chimeric molecules - Boehringer Ingelheim/University of Dundee

Latest Information Update: 22 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim; University of Dundee
  • Class
  • Mechanism of Action Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Immunological disorders; Respiration disorders

Most Recent Events

  • 14 Jul 2016 Early research in Respiration disorders, Cancer and Immunological disorders in Germany (unspecified route)
  • 14 Jul 2016 Boehringer Ingelheim and University of Dundee collaborate to develop proteolysis targeting chimeric molecules for the treatment of Cancer, Respiration disorders, and Immunological disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top